Calendar An icon of a desk calendar. Cancel An icon of a circle with a diagonal line across. Caret An icon of a block arrow pointing to the right. Email An icon of a paper envelope. Facebook An icon of the Facebook "f" mark. Google An icon of the Google "G" mark. Linked In An icon of the Linked In "in" mark. Logout An icon representing logout. Profile An icon that resembles human head and shoulders. Telephone An icon of a traditional telephone receiver. Tick An icon of a tick mark. Is Public An icon of a human eye and eyelashes. Is Not Public An icon of a human eye and eyelashes with a diagonal line through it. Pause Icon A two-lined pause icon for stopping interactions. Quote Mark A opening quote mark. Quote Mark A closing quote mark. Arrow An icon of an arrow. Folder An icon of a paper folder. Breaking An icon of an exclamation mark on a circular background. Camera An icon of a digital camera. Caret An icon of a caret arrow. Clock An icon of a clock face. Close An icon of the an X shape. Close Icon An icon used to represent where to interact to collapse or dismiss a component Comment An icon of a speech bubble. Comments An icon of a speech bubble, denoting user comments. Ellipsis An icon of 3 horizontal dots. Envelope An icon of a paper envelope. Facebook An icon of a facebook f logo. Camera An icon of a digital camera. Home An icon of a house. Instagram An icon of the Instagram logo. LinkedIn An icon of the LinkedIn logo. Magnifying Glass An icon of a magnifying glass. Search Icon A magnifying glass icon that is used to represent the function of searching. Menu An icon of 3 horizontal lines. Hamburger Menu Icon An icon used to represent a collapsed menu. Next An icon of an arrow pointing to the right. Notice An explanation mark centred inside a circle. Previous An icon of an arrow pointing to the left. Rating An icon of a star. Tag An icon of a tag. Twitter An icon of the Twitter logo. Video Camera An icon of a video camera shape. Speech Bubble Icon A icon displaying a speech bubble WhatsApp An icon of the WhatsApp logo. Information An icon of an information logo. Plus A mathematical 'plus' symbol. Duration An icon indicating Time. Success Tick An icon of a green tick. Success Tick Timeout An icon of a greyed out success tick. Loading Spinner An icon of a loading spinner.

Oxford Biomedica revenues double after Covid vaccine contract boost

Staff work in a laboratory at Oxbox Biomedica (Steve Parsons/PA)
Staff work in a laboratory at Oxbox Biomedica (Steve Parsons/PA)

Oxford Biomedica has said Covid-19 vaccine manufacturing contracts helped revenues more than double over the first half of 2021.

The gene and cell therapy group saw shares jump on Wednesday after it also announced an investment from vaccine developer Serum Institute of India.

Oxford Biomedica said its revenues for the six months to June soared by 139% as a result of its vaccine agreement with AstraZeneca.

It said the production contract will mean revenue in the second half will stay at similar levels.

The group’s bioprocessing and commercial development arm saw a 223% leap in revenues over the past six months due to vaccine production, it said.

The company also confirmed that Serum Institute of India invested £50 million in the company in exchange for shares worth 3.9% of the FTSE 250 group.

John Dawson, Oxford Biomedica’s chief executive, said: “Everyone at Oxford Biomedica can be truly proud of what they have continued to achieve in 2021.

“The tireless commitment of the whole team has helped to save thousands of lives, in line with our mission, whilst gaining global recognition for our role in the fight against Covid-19.

“The exceptional financial results that we have reported reflect our strong progress across the business as we continue to demonstrate our world-leading expertise in gene and cell therapy.”

Analysts at Liberum hailed a “strong set” of results and highlighted that earnings projections of between £35 million and £40 million for the current year are ahead of previous forecasts.

Shares in the company increased by 5.6% to 1,561p in early trading.

Already a subscriber? Sign in

[[title]]

[[text]]